



**Randy L. Socol**

**Partner**

randy.socol@dlapiper.com

**San Diego (Golden Triangle)**

**Los Angeles (Century City)**

T: +1 858 677 1457

F: +1 858 638 5057

Randy Socol represents established and emerging growth companies in the technology, biotechnology, healthcare, sports, media and entertainment sectors, counseling founders, management and boards, and handling matters ranging from corporate formation and governance, equity and debt financings, mergers and acquisitions and capital markets transactions. In addition, he also represents venture capital and private equity firms, corporate and strategic investors and acquirors that finance and acquire these emerging growth companies.

In addition to providing strategic and corporate counseling, his practice encompasses venture capital financings, mergers and acquisitions, debt financings, public offerings, equity and compensation matters and corporate governance.

Randy currently splits his time between DLA Piper's San Diego and Los Angeles offices and is a member of the firm's US Emerging Growth and Venture Capital leadership group and the head of the firm's Southern California Emerging Company and Venture Capital practice, as well as a founding member of the firm's Corporate Venture Leadership Group.

- Corporate
- Mergers and Acquisitions
- Emerging Growth and Venture Capital
- Capital Markets
- Intellectual Property and Technology
- Regulatory and Government Affairs
  
- Life Sciences
- Healthcare

Randy has represented emerging growth companies and venture capital and strategic investors in more than 1,000 equity and debt financing transactions. Randy's representation of emerging growth companies, including in connection with financing transactions led by some of the world's leading venture capital and corporate investors, has included AbViro, Aspen Neuroscience, aTyr Pharma, Ceregene, Citadel Defense Company, Cloudbeds, Cordial Experience, Cradle Genomics, Ecwid, EdgeCast Networks, Epic Sciences, Eventful, Flock Freight, Formation, GovX, inVia Robotics, Iterion Therapeutics, LLamasoft, Locanabio, MindTouch, mPulse Mobile, OpenPath Security, Pindrop Security, Qwick, Raken, RetailNext, RingDNA, Science 37, Seraphina Therapeutics, Shape Therapeutics, Sidecar Health, Snap! Mobile, Sun Genomics, TakeLessons.com, The Honest Kitchen, Truvian Sciences, Verse.io, WithMe Health,

Zebit, and Zeakal.

Randy has also represented venture capital firms and strategic investors in debt and equity financing transactions with emerging growth companies, including AIG, BCG Digital Ventures, Cambia Health Solutions, Counterpart Ventures, Deerfield Management Company, DFJ Frontier, dRx Capital, Echo Health Partners, Eldridge Industries, Elysian Park Ventures, Emergence Capital Partners, Endeavour Vision, Ericsson Ventures, Experian, Finistere Ventures, Goldfinch Partners, H.I.G. Capital, Keshif Ventures, Life Technologies Corporation, Lux Ventures, M12 (the venture arm of Microsoft), McKesson Ventures, MedVest Capital Partners, Mitsui, NIKE, Novartis, Qualcomm Ventures, Redmile Group, Sante Ventures, Sorenson Ventures, Steamboat Ventures, TVC Capital, and Upfront Ventures.

Randy also regularly represents both acquirors and selling companies in merger and acquisition transactions, including acquirors such as QUALCOMM Incorporated, NIKE, Inc., Breg, Inc., and Life Technologies Corporation in acquisition transactions. Notable recent acquisitions have included the representation of NIKE, Inc. in its acquisitions of Celect, Inc., Platform Orthopedic Solutions and Invertex Ltd., Speakeasy, and Zodiac, and QUALCOMM Incorporated in its acquisitions of Flarion Technologies, Capsule Technologies, KMeI Robotics, Black Sands Technologies and Healthy Circles, as well as in acquisitions of assets from RF Micro Devices, Advanced Micro Devices and Rapid Bridge, and in its sale of its QUALCOMM Life division to Francisco Partners.

Randy has also represented numerous companies in sell-side transactions constituting successful liquidation events, such as EdgeCast Networks in its acquisition by Verizon, AbVitro, Inc. in its acquisition by Juno Therapeutics, Llamasoft in its acquisition by TPG, Eventful, Inc. in its acquisition by CBS, Ceregene, Inc. in its acquisition by Sangamo BioSciences, Gehry Technologies in its acquisition by Trimble Navigation, StackIQ in its acquisition by Teradata Corporation, Zementis in its acquisition by Software AG, ClearAccess, Inc. in its acquisition by Cisco Systems, Inc., and SmartRG in its acquisition by ADTRAN.

## CREDENTIALS

---

### Admissions

- California

### Recognitions

*The Legal 500 United States* has recognized Randy for his venture capital and emerging companies practice, noting that Randy is 'exceptional', 'fantastic' and 'a seasoned veteran'.

*Chambers USA* has recognized Randy in its Venture Capital, Startups & Emerging Companies, and Corporate/M&A categories, and in 2021, he was ranked in Band 2 for Corporate/M&A in San Diego. He is noted by sources as someone who is "an amazing attorney," "very active when on a transaction" and "very engaged." "Besides his depth of knowledge and experience, he is an eloquent and articulate communicator," sources said. Randy is "very good at being responsive, looking at the big picture and understanding the practice of law," and he "has great knowledge of the space and brings the right personality to the deal."

*San Diego Super Lawyers Magazine* has recognized Randy in 2017 and 2018 as a "Super Lawyer" in the area of Mergers and Acquisitions.

*The San Diego Business Journal* has recognized Randy on its annual SD500 list of influential people for several years.

### Education

- J.D., University of Michigan 1999
- B.A., Northwestern University 1996  
History

### Memberships

- California and San Diego County Bar Associations
- CONNECT w/San Diego Venture Group, Board of Directors

- UCSD Entrepreneur Challenge, Pro Bono Counsel
- Pro Bono Counsel for Ad Astra Ventures, an accelerator focused on female led start-ups

## NEWS

---

### **DLA Piper advises Aspen Neuroscience in its US\$147.5 million Series B financing**

18 May 2022

DLA Piper advised Aspen Neuroscience, a private biotechnology company developing autologous cell therapies, in the closing of its US\$147.5 million Series B funding, which would go towards the clinical trials of company's first iPSC-derived autologous neuron replacement treatment for Parkinson's disease.

---

### **DLA Piper advises mPulse Mobile in growth investment from PSG**

20 January 2022

DLA Piper represented mPulse Mobile, a leader in conversational AI and digital engagement solutions for the healthcare industry, in a growth investment from PSG, a leading growth equity firm partnering with middle-market software and technology-enabled services companies.

---

### **DLA Piper advises Wildfire Systems in US\$15 million Series A financing**

9 September 2021

DLA Piper represented Wildfire Systems, an innovative financial technology platform that powers reward and loyalty programs, in a US\$15 million Series A funding round co-led by TTV Capital and QED Investors.

---

### **DLA Piper advises Truvian Sciences in oversubscribed US\$105 million Series C financing**

24 February 2021

DLA Piper represented Truvian Sciences in its recent oversubscribed US\$105 million Series C financing.

---

### **DLA Piper advises Pairwise in US\$90 million Series B financing**

5 February 2021

DLA Piper represented food technology company Pairwise in its recent US\$90 Series B financing.

---

### **DLA Piper advises Sidecar Health in US\$125 million Series C financing**

3 February 2021

DLA Piper represented health insurtech company Sidecar Health in its recent US\$125 Series C financing, resulting in its subsequent valuation at US\$1 billion.

---

### **DLA Piper advises Locanabio in its US\$100 million Series B financing**

15 December 2020

DLA Piper represented Locanabio, an RNA-targeting gene therapy company focused on developing life-changing therapies for patients with severe neurodegenerative, neuromuscular and retinal diseases, in its recent US\$100 million Series B financing led by Vida Ventures.

---

### **DLA Piper advises Flock Freight in its US\$113.5 million Series C financing**

3 December 2020

DLA Piper represented Flock Freight, a San Diego-based digital logistics provider that offers a shared truckload shipping solution for businesses, in its recent US\$113.5 million Series C financing led by Softbank Vision Fund 2, with participation from existing investors SignalFire, GLP Capital Partners, and GV, as well as a new minority investment by strategic partner Volvo Group Venture Capital.

---

### **Three DLA Piper partners named to *San Diego Business Journal's* SD500 list of influential people**

1 December 2020

DLA Piper is pleased to announce that Corporate partners Michael Brown, Larry Nishnick and Randy Socol have been named to the *San Diego Business Journals* SD500 list of the most influential people in San Diego that are making a significant impact on the business community.

---

### **DLA Piper advises Openpath in its US\$36 million Series C financing**

24 July 2020

DLA Piper represented Openpath in its US\$36 million Series C financing led by Greycroft, with participation from Okta Ventures, LPC Ventures, Allegion Ventures and Sentre, including follow-on from existing investors.

---

## **MEDIA MENTIONS**

- "Coronavirus-Disrupted Drug Firm's \$12M Ch. 11 Loan Gets OK," *Law360*, March 12, 2020